MedTrace Logo

Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers

NCT01766115 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-08-13

No results posted yet for this study

Summary

To assess the safety and tolerability of the use of telaprevir in the setting of post-exposure prophylaxis among HCW exposed to HCV genotype 1 or genotype 2.

To assess the election rate of postexposure prophylaxis for HCV-related occupational exposures in HCW.

Conditions

  • Viral Hepatitis C

Interventions

DRUG

Telaprevir

HCV Protease Inhibitor

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Raymond T. Chung, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01766115 on ClinicalTrials.gov